REFERENCES
- Talcott J A, Siegel R D, Finberg R, Goldman L. Risk assesment in cancer patients with fever and neutropenia: a prospective two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316–322, [PUBMED], [INFOTRIEVE], [CSA]
- Pizzo P A, Halthorn J W, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986; 315: 552–558, [PUBMED], [INFOTRIEVE], [CSA]
- Hughes W T, Armstrong D, Bodey G P, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730–751, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ray-Coquard I, Ghesquiere H, Bechelot T, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumors and lymphomas. Br J Cancer. 2001; 85: 816–822, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Choi C W, Sung H J, Park H H, et al. Early lymphocytopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol. 2003; 73: 263–266, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ray-Coquard I, Borg C, Bachelot T H, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003; 88: 181–186, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Blay J Y, Chauvin F, Cesne L, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996; 14: 636–643, [PUBMED], [INFOTRIEVE], [CSA]
- Mutsumi K, Fumihiro O, Yuji K, et al. Early monocytopenia after chemotherapy as a risk factor for neutropenia. Am J Clin Oncol. 1999; 22: 103–105, [CSA], [CROSSREF]
- Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide and decarbazine in 108 patients with metastatic or unresectable sarcoma an no prior chemotherapy. J Clin Oncol. 1989; 7: 1208–1216, [PUBMED], [INFOTRIEVE], [CSA]
- Velasquez W, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone. Blood. 1988; 72: 117–122, [CSA]
- Fagioli F, Biasin E, Mastrodicasa L, et al. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer. 2004; 100: 2215–2221, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fiorillo A, Maggi G, Greco N, et al. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. J Neurooncol. 2004; 66: 179–185, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Miser J S, Kinsella T J, Triche T J, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5: 1191–1198, [PUBMED], [INFOTRIEVE], [CSA]
- Bennet C L, Weeks J A, Somerfield M R, et al. Use of hematopoietic colony-stimulating factors; comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999; 17: 3676–3681, [CSA]
- The American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol. 1994; 12: 2471–2508, [CSA]
- Metcalf D. Hematopoietic regulators: redundancy or subtlety?. Blood. 1993; 82: 3515–3523, [PUBMED], [INFOTRIEVE], [CSA]
- Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med. 1991; 325: 164–170, [PUBMED], [INFOTRIEVE], [CSA]
- Lyman G H, Layman C G, Sanderson R A, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993; 85: 488–493, [PUBMED], [INFOTRIEVE], [CSA]